CYTK in the 13F filings
Cytokinetics Inc · CUSIP 23282W605
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 12 Feb 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 11 listed it in both
- Shares listed
- 24,183,373
- combined, among listed positions
- Reported value
- $1.1bn
- combined, at the quarter end
Among the 94 comparable managers: 5 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CYTK in Q4 2024
11 of 11 holders
Largest increases and reductions, by shares
Increases
- Marshall Wace LLPexisting position · 2,153,313 shares now+279,612
- Wellington Management Group LLPexisting position · 7,888,697 shares now+113,727
- Hudson Bay Capital Management LPexisting position · 141,269 shares now+73,769
- Two Sigma Advisers LPexisting position · 226,400 shares now+11,700
- Winton Group Ltdexisting position · 19,005 shares now+9,210
Reductions
- Fidelity (FMR LLC)existing position · 10,794,686 shares now-1,299,568
- Janus Henderson Group Ltdexisting position · 1,024,417 shares now-119,413
- AllianceBernstein LPexisting position · 1,595,324 shares now-65,690
- Davidson Kempner Capital Management LPexisting position · 179,061 shares now-23,981
- Woodline Partners LPexisting position · 126,201 shares now-2,834
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
- Farallon Capital Management LLCwas $5.4m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2014 | 1 | $128k | n.a. | n.a. |
| Q4 2015 | 2 | $14m | n.a. | n.a. |
| Q1 2016 | 1 | $8.6m | n.a. | n.a. |
| Q2 2016 | 1 | $3.2m | n.a. | n.a. |
| Q3 2016 | 1 | $184k | n.a. | n.a. |
| Q1 2017 | 1 | $4.3m | n.a. | n.a. |
| Q2 2017 | 2 | $9.9m | n.a. | n.a. |
| Q3 2017 | 2 | $18m | n.a. | n.a. |
| Q2 2018 | 1 | $374k | n.a. | n.a. |
| Q3 2018 | 1 | $349k | n.a. | n.a. |
| Q4 2018 | 1 | $224k | n.a. | n.a. |
| Q1 2019 | 1 | $513k | n.a. | n.a. |
| Q2 2019 | 2 | $7.5m | n.a. | n.a. |
| Q3 2019 | 2 | $5.5m | n.a. | n.a. |
| Q4 2019 | 3 | $35m | n.a. | n.a. |
| Q1 2020 | 6 | $20m | n.a. | n.a. |
| Q2 2020 | 6 | $75m | n.a. | n.a. |
| Q3 2020 | 5 | $114m | n.a. | n.a. |
| Q4 2020 | 3 | $90m | n.a. | n.a. |
| Q1 2021 | 3 | $90m | n.a. | n.a. |
| Q2 2021 | 2 | $74m | n.a. | n.a. |
| Q3 2021 | 7 | $643m | n.a. | n.a. |
| Q4 2021 | 10 | $794m | n.a. | n.a. |
| Q1 2022 | 6 | $624m | n.a. | n.a. |
| Q2 2022 | 10 | $1.0bn | n.a. | n.a. |
| Q3 2022 | 9 | $1.0bn | n.a. | n.a. |
| Q4 2022 | 12 | $1.1bn | n.a. | n.a. |
| Q1 2023 | 11 | $895m | n.a. | n.a. |
| Q2 2023 | 8 | $781m | n.a. | n.a. |
| Q3 2023 | 10 | $753m | n.a. | n.a. |
| Q4 2023 | 12 | $2.4bn | 8 | 4 |
| Q1 2024 | 15 | $1.8bn | 10 | 5 |
| Q2 2024 | 16 | $1.5bn | 10 | 4 |
| Q3 2024 | 15 | $1.5bn | 10 | 3 |
| Q4 2024 | 11 | $1.1bn | 5 | 6 |
| Q1 2025 | 9 | $544m | 7 | 1 |
| Q2 2025 | 4 | $268m | 1 | 2 |
| Q3 2025 | 6 | $1.3bn | 4 | 2 |
| Q4 2025 | 8 | $1.5bn | 17 | 11 |
| Q1 2026 | 11 | $1.5bn | 15 | 16 |
| Q2 2026 | 12 | $1.3bn | 23 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CYTK and LLY →CYTK and JNJ →CYTK and VRTX →Choose a stock to compare with CYTK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CYTK, latest filings →Back to the 13F Explorer →